Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study

Bodd, Monica; Locke, Susan C.; Wolf, Steve P; Antonia, Scott; Crawford, Jeffrey; Hartman, John D.; Herring, Kris; Ready, Neal; Stinchcombe, Thomas E.; Troy, Jesse D.; Williams, Chakita; Clarke, Jeffrey; LeBlanc, Thomas W.

doi:10.1016/j.lungcan.2022.11.010

Lung Cancer

2023

DOI: 10.1016/j.lungcan.2022.11.010

|View full text |Cite

Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study

Monica Bodd

Susan C. Locke²,

Steve P Wolf³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Güven,

Thong,

Arndt

2024

J Cancer Surviv

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) have become a central part of cancer care. However, the survivorship outcomes in patients treated with ICIs are understudied. Therefore, we conducted a scoping review to evaluate the current status of the field and to establish research gaps regarding survivorship outcomes with ICIs in real-life cohorts. Methods We used the Web of Science, PubMed, and Embase databases to systematically filter published studies with real-life cohorts from January 1, 2010, until October 19, 2022. Studies evaluating at least one survivorship outcome in ICI-treated patients were included. Results A total of 39 papers were included. Quality of life (QoL) (n = 23), toxicity burden (n = 16), and psychosocial issues (n = 9) were the most frequently evaluated survivorship outcomes. Anti-PD-1/PD-L1 monotherapy and a response to treatment were associated with better QoL. In addition, the ICIs were associated with grade 3 or higher immune-related adverse events (irAEs) in 10–15% and late/long-term irAEs in 20–30% of the survivors. Regarding psychosocial problems, over 30% of survivors showed evidence of anxiety and depression, and 30–40% of survivors reported neurocognitive impairments. Conclusion The survivors treated with ICIs have impairments in most survivorship domains. Further research is needed to gather data on the understudied survivorship outcomes like late and long-term effects, fertility, financial toxicity, and return to work in survivors treated with ICIs. Implications for Cancer Survivors Available evidence demonstrates that a significant portion of survivors treated with ICIs have a significant toxicity burden, lower QoL than the general population, and a high rate of psychosocial problems.

show abstract

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Güven,

Thong,

Arndt

2024

J Cancer Surviv

View full text Add to dashboard Cite

show abstract

Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer

Oswalt,

Nakatani,

Troy

et al. 2024

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study

Cited by 2 publications

References 36 publications

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About